All posts by: Jocelyn Cao

About Jocelyn Cao

Read the full press release here Waisman Biomanufacturing at the University of Wisconsin–Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by California-based biotech company GigaGen. The drug, called GIGA-2050, uses a new approach similar to treating COVID-19 patients with convalescent plasma, or blood products from people recovering (convalescing) from an […]

Read the full press release here Exact Sciences has won regulatory approval to process COVID-19 tests from specimens taken by people in their homes. The Food and Drug Administration gave approval for the company to test specimens collected using two home collection kits, including one from Exact Sciences. The tests must be ordered by a […]

Read the full press release here Healthy living blogger Becca Ludlum knows all too well the physical and mental toll Chronic Migraine can have. She experienced self-described ‘daily unbreaking migraine attacks.’ Her story is more common than you think. In the U.S., more than 3.3 million adults live with Chronic Migraine1, and people who experience […]

Read the full press release here Travel restrictions. Suspension of face-to-face human-subjects research. Conference cancellations. While research has gradually restarted on campus since the COVID-19 pandemic forced a nearly complete shutdown of in-person activity in the spring, many faculty and students are still feeling the effects on their research. To help mitigate some of those […]

Read the full press release here The University of Wisconsin Carbone Cancer Center has the go-ahead to start clinical trials on a first-in-human cell therapy to treat a common side effect of radiation therapy. This investigational new drug license, or IND, recently issued by the Food and Drug Administration will allow UW oncologists to study […]

Read the full press release here Researchers at the nonprofit Usona Institute in Fitchburg are looking to improve how depression is treated by turning to an unorthodox medicine: psychedelic mushrooms.  These so-called “magic mushrooms” contain a substance known as psilocybin, which has shown promising results in early clinical trials for patients with clinical depression. According […]